Treatment of GDM with Metformin tied to Favourable Lipid Profile in Offsprings

Key Findings of the Study were:

• Upon analysis, the researchers found no difference in 9-year-old offspring's anthropometric variables, including body mass index and waist-to-height ratio.
• However, they noted that offspring in the metformin group had higher high-density lipoprotein cholesterol (HDL-C) concentrations (1.72 vs 1.54 mmol/L) but lower low-density lipoprotein cholesterol (2.39 vs 2.58 mmol/L) and apolipoprotein B concentrations (0.63 vs 0.67g/L) than the offspring in the insulin group.
• They also noted that the difference in the HDL-C concentration was found to be significant only in boys.
• They observed that the 2-hour glucose value in the oral glucose tolerance test was 0.6 mmol/L lower in boys from the metformin group than in those from the insulin group.

The authors concluded, "Metformin treatment for GDM is associated with similar offspring growth and glucose metabolism but a more favourable lipid profile at the age of 9 years as compared to insulin treatment."

For further information:

DOI: https://doi.org/10.1111/dom.14589